Kynamro Reduces Risk of Cardiovascular Events in Familial Hypercholesterolemia Patients, page-79

Another good read on PATENT EXPIRY Pfizer are at the head of these losses at the moment and
also on the fast tracking of new drugs


Big pharmaceutical players risk losing another $188 billion in sales through 2023 as a number of their key drugs lose patent exclusivity. Bidness Etc highlights how these companies are gearing up to minimize losses



Large pharmaceuticals can also minimize the risk by acquiring small-cap biotechs with late-stage development products in their portfolio in order to enhance and diversify their own pipeline

IE   PFIZER - ANP


Pharmaceuticals will be increasingly interested in speeding up the processes involved in getting their drugs to the market through breakthrough therapy designation, fast-track designation, accelerated approvals, and priority review programs.

A success story in this regard is that of AstraZeneca, which is expected to file for marketing approvals for its cancer drug AZD9291 in 2015, in a record 2.5 years since enrollment by taking advantage of breakthrough therapy designation status granted by the US Food and Drug Administration.

2.5 years cancer drug to market  again hopefully management are all over this.

with the problems related to the MS drugs on market one would have to hope the FDA would see 1102 as a breakthrough therapy and fast track designate the drug

http://www.bidnessetc.com/29932-patent-cliff-a-lethal-blow-to-big-pharma-or-just-a-tiny-bump/

Exciting times ahead just hope its sooner rather than later